Moderna has tapped Swedish long-acting drug formulation company Nanexa to improve the delivery of up to five injectable therapies. The heavily back-loaded deal will see Moderna hand over just $3 ...

Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 6.4% in the afternoon session after a major long-term study from France indicated that its COVID-19 vaccine was safe and effective. The ...

An expert panel of the EU drug regulator, the European Medicines Agency (EMA), endorsed seven new medicines for approval this week, including a cancer drug from ImmunityBio (IBRX) and Moderna's (MRNA) ...

Moderna's narrative is shifting as analysts modestly trim their fair value from $37.32 to $35.78 per share and nudge the discount rate from 7.13% to 7.13%, reflecting a slightly higher required return ...

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use has recommended granting marketing authorization for Moderna’s new RNA-based vaccine, mNexspike, for preventing ...

The U.S. is in "big danger" of falling behind in vaccine technology research as government funding declines and vaccine skepticism rises, according to Moderna (MRNA) co-founder and chairman Noubar ...

Moderna Inc. (NASDAQ:MRNA) is one of the high short interest stocks to buy right now. On November 20, Moderna announced that it had secured a five-year loan of $1.5 billion from Ares Management Corp ...

Shares of vaccine makers fell Monday after the Food and Drug Administration’s top vaccine regulator said in an internal memo that the agency would introduce stricter vaccine approval rules.